Jason Gotlib
Professor of Medicine · Stanford Health Care
Credentials: · · ·
History
- Present
- Present
- 2000–2003
Stanford University Hematology and Oncology Fellowship (2003) CA
1995–1996
Research
Blood · 2022 · 2,489 citations
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
New England Journal of Medicine · 2012 · 1,753 citations
New England Journal of Medicine · 2003 · 1,319 citations
55 papers · 2 as a fellow
48 papers
39 papers
- SV
35 papers
- DM
30 papers
29 papers
26 papers
24 papers
Grants
- 2019–2020
American Initiative in Mast Cell Diseases (AIM)
National Center for Advancing Translational Sciences · R13
Contact PI · $15K · Stanford University
- 2001–2007
FTI Biology & Treatment of Myeloproliferative Disorders
National Heart, Lung, and Blood Institute · K23
Contact PI · $594.7K · Stanford University
Clinical trials
- 2015–2017
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Principal investigator · Terminated · Phase 2
Jason Robert Gotlib
- 2013–2017
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Principal investigator · Completed · Phase 2
Jason Robert Gotlib
- 2009–2012
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Principal investigator · Terminated · Phase 1
Jason Robert Gotlib
- 2009–2012
Principal investigator · Completed · Phase 1, Phase 2
Sierra Oncology LLC - a GSK company